Voya Investment Management LLC Buys 542,319 Shares of MacroGenics Inc (MGNX)
Voya Investment Management LLC boosted its stake in shares of MacroGenics Inc (NASDAQ:MGNX) by 149.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 905,752 shares of the biopharmaceutical company’s stock after buying an additional 542,319 shares during the period. Voya Investment Management LLC owned approximately 2.14% of MacroGenics worth $18,703,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in MacroGenics by 17.5% in the 2nd quarter. BlackRock Inc. now owns 3,122,067 shares of the biopharmaceutical company’s stock valued at $64,472,000 after acquiring an additional 465,948 shares during the last quarter. Millennium Management LLC grew its position in MacroGenics by 86.2% in the 1st quarter. Millennium Management LLC now owns 897,982 shares of the biopharmaceutical company’s stock valued at $22,593,000 after acquiring an additional 415,681 shares during the last quarter. Victory Capital Management Inc. bought a new position in MacroGenics in the 1st quarter valued at $4,443,000. OppenheimerFunds Inc. grew its position in MacroGenics by 4.1% in the 2nd quarter. OppenheimerFunds Inc. now owns 4,109,540 shares of the biopharmaceutical company’s stock valued at $84,862,000 after acquiring an additional 160,170 shares during the last quarter. Finally, Spark Investment Management LLC grew its position in MacroGenics by 67.7% in the 2nd quarter. Spark Investment Management LLC now owns 379,000 shares of the biopharmaceutical company’s stock valued at $7,826,000 after acquiring an additional 153,000 shares during the last quarter. Institutional investors own 92.84% of the company’s stock.
Several equities analysts have commented on the company. ValuEngine raised MacroGenics from a “hold” rating to a “buy” rating in a research report on Thursday, September 13th. HC Wainwright set a $34.00 price target on MacroGenics and gave the stock a “buy” rating in a research report on Monday, June 4th. BidaskClub raised MacroGenics from a “hold” rating to a “buy” rating in a research report on Friday, June 22nd. Evercore ISI initiated coverage on MacroGenics in a research report on Thursday, May 31st. They set an “outperform” rating and a $33.00 price target on the stock. Finally, TheStreet downgraded MacroGenics from a “c” rating to a “d+” rating in a research report on Wednesday, May 23rd. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. MacroGenics currently has a consensus rating of “Buy” and an average price target of $30.50.
MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.17. MacroGenics had a negative return on equity of 13.01% and a negative net margin of 19.20%. The business had revenue of $18.83 million for the quarter, compared to the consensus estimate of $4.41 million. research analysts forecast that MacroGenics Inc will post -4.77 earnings per share for the current fiscal year.
MacroGenics, Inc, a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.
Recommended Story: How are the companies in the S&P 500 selected?
Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics Inc (NASDAQ:MGNX).
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.